These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2949663)

  • 1. [Parlodel treatment in the diagnosis of hyperprolactinemia].
    Pamfamirov IuK; Golubev VA; Zaets VV; Semeniuta AN
    Akush Ginekol (Mosk); 1986 Nov; (11):67-9. PubMed ID: 2949663
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinico-diagnostic indicators and late results of the treatment of infertility in hyperprolactinemia].
    Ovsiannikova TV; Pshenichnikova TIa; Burdina LM; Korneeva IE
    Akush Ginekol (Mosk); 1989 Oct; (10):46-9. PubMed ID: 2618956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic and therapeutic approach to hyperprolactinemia].
    Rüedi B
    Rev Med Suisse Romande; 1995 May; 115(5):399-401. PubMed ID: 7770687
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of galactorrhea-amenorrhea.
    De Leon FD
    Am Fam Physician; 1985 Dec; 32(6):121-4. PubMed ID: 4072865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
    Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
    Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
    Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of uremic hypogonadism with parlodel].
    Kukhtevich AV; Ermolenko VM; Dedov II; Mel'nichenko GA; Gitel' EP
    Ter Arkh; 1985; 57(12):39-41. PubMed ID: 4089767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of hyperprolactinemia in the genesis of menstrual cycle disorders and their correction with parlodel].
    Manuilova IA; Sotnikova EI
    Akush Ginekol (Mosk); 1984 May; (5):15-6. PubMed ID: 6465440
    [No Abstract]   [Full Text] [Related]  

  • 9. Galactorrhea in a 14-year-old girl.
    Panamonta O; Pakawut N
    J Med Assoc Thai; 2006 Aug; 89(8):1304-7. PubMed ID: 17048445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoreactive prolactin in breast milk and plasma of women with hyperprolactinemia, galactorrhea and menstrual dysfunction.
    Yuen BH
    Int J Fertil; 1986; 31(1):67-70. PubMed ID: 2908279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
    Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
    Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The results of using parlodel in hyperprolactinemia].
    Mel'nichenko GA; Gitel' EP; Romantsova TI
    Probl Endokrinol (Mosk); 1990; 36(3):29-33. PubMed ID: 2395828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperprolactinemia and ovarian function].
    Tscherne G
    Gynakol Rundsch; 1986; 26 Suppl 2():165-70. PubMed ID: 3570070
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hyperprolactinemia. Reproductive consequences].
    Austin KL
    Rev Med Panama; 1989 Sep; 14(3):121-7. PubMed ID: 2813875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinemia in children: clinical features and long-term results.
    Catli G; Abaci A; Altincik A; Demir K; Can S; Buyukgebiz A; Bober E
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1123-8. PubMed ID: 23329759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the role of bromocriptine in the primary treatment of prolactinomas.
    Lamberts SW
    Neth J Med; 1988 Apr; 32(3-4):107-11. PubMed ID: 3362264
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-acting injectable bromocriptine treatment for macroprolactinomas.
    Van Cutsem EJ; Lamberts SW
    Neth J Med; 1988 Apr; 32(3-4):112-7. PubMed ID: 3362265
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperprolactinaemia in Zimbabwean women.
    Kasule J; Chimbira TH
    Cent Afr J Med; 1987 Jul; 33(7):173-8. PubMed ID: 3455362
    [No Abstract]   [Full Text] [Related]  

  • 20. New perspectives in medical management of hyperprolactinemia.
    Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Sileo F; Ferrari L; Stroppa S; Gualteroni L; Pagani G
    Endocrinol Exp; 1990 Mar; 24(1-2):159-66. PubMed ID: 2361458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.